Cyclandelate in the treatment of vertigo of circulatory origin. A study in general practice

Area of Science:

• Pharmacology and Therapeutics
• Neurology
• General Practice

Background:

• Vertigo of circulatory origin is a common condition presenting in general practice.
• Existing treatments may have limitations, necessitating evaluation of alternative therapies.
• Patient populations with circulatory issues, including thrombosis and atherosclerosis, often experience severe vertigo symptoms.

Purpose of the Study:

• To evaluate the efficacy of cyclandelate in managing vertigo of circulatory origin.
• To assess the impact of cyclandelate on vertigo symptom frequency, severity, and duration.
• To determine the utility of cyclandelate within a general practice setting.

Main Methods:

• A multicentre study involving 622 patients diagnosed with vertigo of circulatory origin.
• Patients received a daily dosage of 1600 mg of cyclandelate for a 3-month treatment period.
• Symptom assessment included global vertigo scores and specific measures for frequency, severity, and duration.

Main Results:

• The average global vertigo score decreased significantly from 5.57 to 2.12 (on a 0-10 scale).
• Average scores for vertigo frequency, severity, and duration also showed marked reductions (from approx. 2.5 to 0.9).
• Patients previously treated with other anti-ischaemic drugs responded similarly to cyclandelate.

Conclusions:

• Cyclandelate demonstrates significant efficacy in reducing vertigo symptoms in patients with circulatory issues.
• The findings suggest cyclandelate is a potentially useful therapeutic option for vertigo of circulatory origin in general practice.
• The drug's effectiveness was observed across diverse patient subgroups, including those with risk factors like atherosclerosis.